Actively Recruiting
A Real-world Study of Camrelizumab Combined With Apatinib Mesylate in Unresectable Hepatocellular Carcinoma
Led by Meng Chao Hepatobiliary Hospital of Fujian Medical University · Updated on 2025-05-13
300
Participants Needed
1
Research Sites
184 weeks
Total Duration
On this page
Sponsors
M
Meng Chao Hepatobiliary Hospital of Fujian Medical University
Lead Sponsor
S
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Collaborating Sponsor
AI-Summary
What this Trial Is About
To evaluate the efficacy and safety of camrelizumab combined with apatinib mesylate in the treatment of unresectable hepatocellular carcinoma.
CONDITIONS
Official Title
A Real-world Study of Camrelizumab Combined With Apatinib Mesylate in Unresectable Hepatocellular Carcinoma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age between 18 and 75 years, male or female
- Diagnosed with hepatocellular carcinoma meeting clinical diagnostic guidelines or confirmed by pathology
- At least one measurable lesion on CT scan according to mRECIST1.1 criteria
- No prior systemic therapy or first-line systemic therapy failure or intolerance
- CNLC stage IIb to IIIb liver cancer
- Child-Pugh liver function grade A or B (score 5-7)
- ECOG performance status score of 0 or 1
- Expected survival time of 12 weeks or more
- If active hepatitis B infection: HBV-DNA ≤ 2000 or antiviral treatment started at least one week before treatment
- Voluntary participation with good compliance and willingness to follow up
You will not qualify if you...
- Pregnant or breastfeeding women
- Contraindications to immunotherapy including post-transplantation, severe autoimmune diseases, organ failure, prior severe immunotherapy reactions, or uncontrolled infections
- Use of immunosuppressive or systemic hormone therapy above 10mg prednisone (or equivalent) within 14 days before enrollment
- Allergy to camrelizumab, apatinib mesylate, or other monoclonal antibodies
- Impaired consciousness, inability to cooperate, or mental illness
- Participation in other clinical trials within the past three months
- Severe failure of major organs such as liver, kidney, heart, lung, or brain
- Other serious concurrent diseases that may risk safety or study completion as judged by investigators
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Mengchao Hepatobiliary Hospital, Fujian Medical University
Fuzhou, Fujian, China
Actively Recruiting
Research Team
Y
Yong yi Zeng
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here